FDA Inspection 1140155 — Joshua Sabari, M.D.
The FDA completed an inspection of Joshua Sabari, M.D. on March 8, 2021 in New York, NY. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- March 8, 2021
- Fiscal Year
- 2021
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- New York, NY (United States)
Additional Details
Clinical Investigator (CI)